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Characterisation of mesenchymal stromal
cells in clinical trial reports: analysis of
published descriptors
Alison J. Wilson1* , Emma Rand1, Andrew J. Webster2 and Paul G. Genever1
Abstract
Background: Mesenchymal stem or stromal cells are the most widely used cell therapy to date. They are
heterogeneous, with variations in growth potential, differentiation capacity and protein expression profile
depending on tissue source and production process. Nomenclature and defining characteristics have been debated
for almost 20 years, yet the generic term ‘MSC’ is used to cover a wide range of cellular phenotypes. Against a
documented lack of definition of cellular populations used in clinical trials, our study evaluated the extent of
characterisation of the cellular population or study drug.
Methods: A literature search of clinical trials involving mesenchymal stem/stromal cells was refined to 84 papers
upon application of pre-defined inclusion/exclusion criteria. Data were extracted covering background trial
information including location, phase, indication, tissue source and details of clinical cell population characterisation
(expression of surface markers, viability, differentiation assays and potency/functionality assays). Descriptive statistics
were applied, and tests of association between groups were explored using Fisher’s exact test for count data with
simulated p value.
Results: Twenty-eight studies (33.3%) include no characterisation data. Forty-five (53.6%) reported average values
per marker for all cell lots used in the trial, and 11 (13.1%) studies included individual values per cell lot. Viability
was reported in 57% of studies. Differentiation was discussed: osteogenesis (29% of papers), adipogenesis (27%),
and chondrogenesis (20%) and other functional assays arose in 7 papers (8%). The extent of characterisation was
not related to the clinical phase of development. Assessment of functionality was very limited and did not always
relate to the likely mechanism of action.
Conclusions: The extent of characterisation was poor and variable. Our findings concur with those in other fields
including bone marrow aspirate and platelet-rich plasma therapy. We discuss the potential implications of these
findings for the use of mesenchymal stem or stromal cells in regenerative medicine, and the importance of
characterisation for transparency and comparability of literature.
Keywords: Mesenchymal stem cells, Mesenchymal stromal cells, Clinical trial, Characterisation, Cell therapy,
Regenerative medicine
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Introduction
Cell-based therapies, often using stem cell populations
from adult tissues, offer substantial potential clinical
benefits but represent considerable scientific and regula-
tory challenges in translation [1–3]. Non-haematopoietic
stem cells have been identified in the bone marrow, with
colony-forming, self-renewal and multi-lineage differen-
tiation capacity demonstrated in vivo [4–7]. These stem
cells have acquired a more general identity in the litera-
ture, in which in vivo properties have been extrapolated
to stromal cells from a wide range of tissues. However,
MSC heterogeneity is well established and present at
every level of analysis. Compared to their bone marrow
counterparts, stromal cells from the umbilical cord, cord
blood, adipose, dental pulp, placenta and many other
sources, exhibit differing marker profiles, differentiation
potential and immunomodulatory properties [8–10].
Clonal populations may differ considerably in their func-
tionality [11–13]. Heterogeneity of morphology and
function has been described even within colonies ex-
panded from single cells [14]. Heterogeneous in origin
and biological properties, these cells are described by a
range of names including mesenchymal stem cell, mes-
enchymal stromal cell and multipotent progenitor cell;
the literature contains many articles discussing identity,
stemness and appropriate nomenclature for these most
widely studied cells in vitro [15–19]. We do not intend
to address the nomenclature issue in this study other
than to explore the choice of terms ‘stem’ and ‘stromal’
versus likely mechanisms of action; thus, we adopt the
acronym ‘MSC’ throughout without prejudice to the ter-
minology debate.
MSCs have become a cornerstone of cell-based ther-
apy and regenerative medicine, due in no small part to a
range of attractive properties including multi-potential
differentiation and expression of immunomodulatory
and anti-inflammatory molecules in vitro, in vivo and in
clinical use [20, 21], although a large-scale clinical suc-
cess has remained elusive [22, 23]. It is apparent that the
use of any cells in regenerative medicine, not least the
broad, ill-defined class represented by the term ‘MSC’,
requires in-depth characterisation of phenotype, trophic
factor expression and potential mechanisms of action
[24].
MSCs are reported to be the most frequently studied
stem cells in clinical trials [25], with almost 1000 clinical
trials registered in the USA alone [26]. The majority of
trials are small, uncontrolled studies with differences in
design making it challenging to compare and contrast
outcomes [27]. A recent analysis examined >1000 stem
cell clinical trials, of which 50% were early phase investi-
gations (phases I–II) [28].
The International Society for Stem Cell Research
(ISSCR) updated guidelines [29] include the need for
standards addressing, amongst other aspects, the report-
ing of stem cell clinical trials. Analysis of 393 completed
stem cell clinical trials against the ISSCR guidelines
highlighted the absence of key data including the pri-
mary and secondary outcomes and called for the devel-
opment of guidelines for publication of, in particular,
early clinical studies [28]. The existing background lit-
erature documents concerns over reporting of cell ther-
apy clinical trials [28, 30, 31], with a lack of clear
definition of the trial intervention (study drug) being
identified as a significant concern [31–34]. This sug-
gested that analysis of the extent of characterisation pa-
rameters being included in papers should be undertaken.
Characterisation and standardisation of the cell-based
product, combined with the determination of optimum
patient characteristics, both to maximise treatment po-
tential and to assist elucidation of mechanisms of action,
are key challenges for cell therapy [18, 27, 35]. As clin-
ical development proceeds, more extensive data should
become available concerning the safety and efficacy of
the product. This published literature should therefore
provide a reasonable picture of the overall clinical utility
of a product.
Cell-based medicines, unlike other novel biological
medicines, may be produced not only by pharmaceutical
companies but also in hospitals by research physicians.
This is permissible to a limited extent in the EU by an
exemption to the requirements of the advanced therapy
medicinal products (ATMP) regulation [36] which pro-
vides for the manufacture of an ATMP for a specific pa-
tient without a marketing authorization, provided the
product is manufactured to specific standards of quality
and produced on a non-routine basis for use in a hos-
pital within the same member state. In the USA, regula-
tions permit the sale of minimally manipulated human
tissues and cells without the Food and Drug Administra-
tion (FDA) approval subject to certain conditions [37].
However, the possibility for manufacture outside of the
standard medicines paradigms, coupled with the ready
supply of dubious miracle cure stories in the media,
makes cell-based ATMPs not only a fertile ground for
extensive study but has also led to various clinics offer-
ing commercial treatments involving unlicensed (un-
approved) medicines [38–40]. Unsurprisingly, the safety
and efficacy of such unregulated cell-based therapies are
of significant concern to regulators [41–43] and the US
FDA has recently issued several ‘Warning Letters’ (for-
mal notification that a company is in violation of federal
law or regulations) [44, 45]. Concerns have been
expressed regarding the rapid progression of MSC-based
therapies to the clinic without a clear understanding of
the biology underpinning potential mechanisms of ac-
tion [46–48]. Indeed, the recent Cochrane review of
MSC in graft-vs-host disease (GvHD) following
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haematopoietic stem cell transplantation concluded that
evidence was both of low quality and not supportive of
MSC efficacy in treating GvHD [49]. The literature cov-
ering clinical trials on ATMPs is thus particularly im-
portant in conveying the true extent of reliable clinical
research in a range of indications, and therefore, the
quality of the data published in this regard should with-
stand scrutiny.
Set against a background of historical concerns over
MSC identity and biological activity and calls for a
clearer definition of cell therapies in clinical trials, here
we have examined trials published in the scientific litera-
ture between 2010 and 2019 that used MSCs in a range
of clinical indications. We evaluated reporting of the ex-
tent of MSC characterisation, defined as information on
the expression of cell surface antigens (CD markers), cell
viability, differentiation potential and functional assays.
The data are made available through “Cell Identity-MSC
Application” (CIDMap) (https://shiny.york.ac.uk/er13/
CIDMap), an interactive web application which we have
developed to allow users to review and perform their
own analyses of our dataset. We discuss the potential
implications of the findings and make recommendations




A literature search of Web of Science was conducted to
identify relevant primary clinical research articles based
on title and abstract content (Fig. 1A). Application of in-
clusion/exclusion criteria (Table 1) to the output of the
initial search (1986 papers) provided the initial database
of papers.
In this study, the term ‘characterisation’ was defined as
information on the expression of cell surface antigens
(cluster of differentiation (CD) markers), cell viability,
differentiation potential and functional assays. Data col-
lection tables were designed to capture a range of char-
acteristics and other relevant study parameters. The
International Society for Cell and Gene Therapy (ISCT)
minimal criteria recommended for defining multipotent
mesenchymal stromal cells [50] (expression of CD73,
CD90, CD105, absence of CD34, CD45, CD14 or
CD11b, CD79α or CD19, HLA-DR expression, plus dif-
ferentiation in vitro to osteo-, chondro- and adipogenic
lineages) were captured. In addition, we noted any men-
tion of expression of a range of other phenotypic
markers reportedly typical for MSCs (CD29, CD44,
CD146, CD166, CD271, STRO-1, MSCA-1, SSEA-4) or
indicative of potential cellular impurities in the MSC
population (CD3, CD13, CD31, CD133). The data cap-
ture strategy included elements of trial description, cell
source and aspects of characterisation (Fig. 1B).
Definitions
Where the paper identified the clinical trial phase, this
was recorded in our analysis. If the stage of clinical de-
velopment was not defined by the authors, a ‘phase’ des-
ignation was entered based on conventional definitions
(see Supplementary Information). The phase term was
then further condensed into three categories: phase I
(first-in-human, safety/initial proof of concept), phase II
(exploratory) and phase III (confirmatory) to explore as-
sociations between the clinical trial phase and the extent
and stringency of characterisation reported.
Mechanism of action ascribed to the MSC within the
trial was assigned based on the authors’ own comments
and discussion. Where the authors did not clearly state
their view, a designation was assigned based on the
broad principle theme of mechanism given most prom-
inence or credence by authors (see Supplementary Infor-
mation). Thus:
 Paracrine = secretion of molecules including
mediators of anti-inflammatory or anti-apoptotic ef-
fects, host cell recruitment or growth factor
expression
 Immune = specifically immunomodulatory effects
e.g. in GvHD, transplant tolerance
 Differentiation = in situ differentiation to site-
appropriate cell type(s) anticipated
 Multi = multiple relevant mechanisms discussed by
authors
 NS = not stated: no discussion, or no clear
preference for any of the possible mechanisms of
action by which cells were likely to achieve the
intended therapeutic effect
The route of administration was recorded using,
where possible, the European Directorate for the
Quality of Medicines standard terms [51]. Potency/
other functionality assays were captured where men-
tioned, including the expression of relevant proteins,
cellular activity assays and differentiation to relevant
lineages. This last is distinct from the recording of
tri-lineage differentiation as part of routine identifica-
tion of MSCs.
The extent of cell surface marker characterisation and
cell viability reported in the literature set was recorded
and articles were categorised as reporting:
1. The percentages of cells which were positive or
negative for phenotypic markers for each batch of
cells
2. The average percentage of cells which were positive
or negative for phenotypic markers across the trial
3. That cells were tested as positive or negative for
phenotypic markers but without the percentages
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4. The cells were of a ‘standard’ phenotype or
referenced published literature
5. No information about phenotypic markers and/or
viability
The number of categories was then reduced to allow
clearer visualisation of the most commonly reported
markers. Reports for which actual values (individual or
averaged) were included were combined into a ‘Per-
formed, value reported’ category. Reports for which it
was stated that tests had been done, but results were not
included, were coded as ‘Performed, value not reported’,
and instances in which there was no information in the
report relating to testing were combined into a ‘Not
mentioned’ category.
Data analysis
Analysis was conducted in R [52] with tidyverse pack-
ages [53] and Microsoft Excel. Descriptive statistics cap-
tured numbers of studies by year, by clinical phase, by
indication, by route of administration and by putative
mechanism of action (MOA). Association between
Fig. 1 Literature search strategy and results. A The schematic shows search terms, refinements and exclusions used. Numbers refer to the total
number of papers remaining at each stage. B Reported characteristics for MSCs in clinical research studies: data elements captured for this
analysis. Basic information on the trial included clinical phase, indication, route of administration and mechanism(s) of action. Specifics of the cell
source included donor details, tissue source and usage (allogeneic/autologous) and the descriptor used by the study: stem/stromal cells or other
nomenclature. Aspects of characterisation reported in the study were captured, focussing on assessment of viability, phenotypic profile,
differentiation capacity and potency evaluations. Reference to ISCT minimal criteria for identification of MSC was also recorded
Wilson et al. Stem Cell Research & Therapy          (2021) 12:360 Page 4 of 15




A literature search of Web of Science was conducted to
identify relevant primary clinical research articles based
on title and abstract content. Figure 1A illustrates the
search strategy and results; Fig. 1B lists the aspects gath-
ered from the papers. Application of inclusion/exclusion
criteria (Table 1) to the output of the initial search (1986
papers) provided the initial database of papers.
Overview of published MSC clinical trials (2010–2019)
A total of 84 papers were included in the analysis. Back-
ground information from each trial was summarised in-
cluding country, clinical phase, indication, route of
administration and potential mechanism(s) of action
(MOA) of the MSCs (Supplementary Information Table
S1).
MSC-based trials were conducted in 27 different coun-
tries. Most studies were conducted in China (15),
followed by the USA (11), Spain (10), Republic of Korea
(9) and Denmark (5) with between 1 and 4 trials origin-
ating from other countries (Fig. 2A). The majority were
at early clinical development (safety/proof-of-concept)
phase; only two confirmatory (phase III) trials were rep-
resented (Fig. 2B). The most frequent routes of adminis-
tration were intravenous (23), intrathecal (16), local
(site-specific) (12), intra-cardiac (11) and intra-articular
(10) (Fig. 2C), reflecting the indications being addressed.
The most common indications concerned the nervous
system (24) of which 11 studies investigated spinal cord
injury repair and five, amyotrophic lateral sclerosis. Car-
diovascular indications (16) were broadly spread across
myocardial infarction, angina and heart failure. There
were 15 reports of musculoskeletal indications of which
the majority, 10 studies, concerned osteoarthritis
(Fig. 2D).
MSC tissue sources
A range of MSC tissue sources was reported, with the
bone marrow representing the most common (51 stud-
ies), followed by the adipose tissue (17 studies) and um-
bilical cord (16 studies) (Fig. 3A). The term ‘umbilical
cord’ was used to cover papers reporting the use of
MSCs isolated from the umbilical cord blood, umbilical
cord and Wharton’s jelly. Autologous cells were used
slightly more frequently than allogeneic cells (51% vs
46%), and two papers reported the use of both autolo-
gous and allogeneic cells in the same study (Fig. 3B).
The term ‘stem’ was much more commonly used than
‘stromal’, with two other individual terms, ‘multipotent
stromal’ and ‘regenerative’ cells also being recorded
(Fig. 3C).
MSC characterisation
Forty-five studies (53.6%) reported the average percent-
age of cells that were positive or negative for each
phenotypic marker tested and/or viability within that
trial (‘trial average’). These were presented either as an
average for all batches or as a statement that all batches
met acceptance criteria (release specification) e.g. ‘all
cells met the specification of >90% expression for
marker X’. Eleven (13.1%) studies reported the percent-
ages of cells which were positive or negative for pheno-
typic markers for each batch of product within a trial
(‘batch average’). Twenty-eight studies (33.3%) reported
no characterisation data. Six of these (7.1%) referred to a
‘standard phenotype’ or other published literature; 9
(10.7%) stated that tests were performed but without
reporting values and 13 studies (15.5%) did not discuss
any testing, control or evaluation of cells prior to admin-
istration to patients (Fig. 4A).
Table 1 Inclusion/exclusion criteria
Inclusion Exclusion
In English Not in English
MSC or mesenchymal stem cells or
mesenchymal stromal cells
Not mesenchymal stem/stromal cells e.g. not stromal vascular fraction, bone marrow aspirate, cord
blood, platelet-rich plasma, bone marrow mononuclear cells, induced pluripotent stem cell-derived
MSC, conditioned medium
‘Tissue-derived’ stem cells Not human cells
Human cells Non-clinical study
Human application (i.e. not non-clinical) In vitro study only
Clinical application (i.e. not in vitro) Forward-looking perspective
Research article Reviews
MSC from any tissue source Published pre-2010
Characterisation of the population for
clinical use
Published 2010–2019
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The extent of reporting of CD markers and viability
tests performed during studies at each clinical phase was
assessed. The most frequent approach was to report
average values, generally a single value representing the
attribute assessed across the entire clinical population.
In each phase of clinical development, there was a large
percentage of trials in which no characterisation data
were reported: 21/54 (39%) of phase I and 10/28 (40%)
of phase II trials (Fig. 4B).
The level of variation in the extent of characterisation
between the 56 papers reporting either trial average or
batch average values was considerable. The largest sub-
set, 15 papers, included only one characteristic reported
by value; in each instance, this was viability. Sixteen (16)
papers reported either 8 or 9 characteristics, and the
remainder covered fewer characteristics (Fig. 4C). There
was no evidence of the association between the clinical
trial phase and the extent and stringency of characterisa-
tion reported.
For the next part of the analysis, the number of char-
acterisation categories was reduced to three—not per-
formed/performed, no value reported/performed, value
reported—to allow clearer visualisation of the most com-
monly reported markers. The markers/viability assay ad-
dressed in each report is shown in Fig. 5A, and the
number of reports addressing each marker/viability is
shown in Fig. 5B. In four studies viability was the only
value reported. Eleven (11) studies reported a value for
viability but did not include the values for other charac-
terisation attributes (CD markers) mentioned within the
Fig. 2 Background trial information. A Origin of clinical research publications, ranked by number from each country represented in the analysis. B
Clinical trials reported in literature by clinical phase, ranked by most commonly represented phase of clinical study. C Route of administration,
ranked by most commonly used in the studies. D Indications addressed by the clinical studies, ranked by most commonly represented indication
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report. Overall, the most commonly evaluated character-
istics were a subset of those recommended by ISCT for
identification of MSCs: CD45 was assessed in 56 studies,
followed by CD105 (51 studies), CD90 (49 studies),
CD34 and CD73 (48 studies). One paper documented an
analysis of the full set of ISCT markers. Studies that in-
cluded data on all three aspects (cellular identity, purity
and viability) comprised 62% of the dataset. Identity and
purity were addressed in 59 studies (70%), and 48 studies
(57%) reported measurement of viability prior to admin-
istration of the cells to trial subjects.
The surface markers recommended by the ISCT as
part of their minimal criteria for identification of multi-
potent mesenchymal stromal cells are highlighted in
Fig. 5. The majority of papers did not report character-
isation in line with the ISCT recommendations although
16 papers did mention or specifically claim compliance.
In vitro differentiation to osteogenic, chondrogenic
and adipogenic lineages is an expected property of
MSCs: this is a key criterion of the ISCT identification
recommendation. Beyond this, the clinical development
of medicinal products is required to include the develop-
ment of one or more potency assays, defined as bio-
logical functional attributes relevant to the anticipated
clinical mechanism of action of the cells. In the majority
of papers, there was no indication that any differenti-
ation potential of the cells had been conducted: osteo-
genesis and adipogenesis assays were mentioned/
discussed in 29% and 27% of studies respectively, chon-
drogenesis in 20% of papers (Fig. 6A). Functional assess-
ments were identified in 6 papers (7%); these included
specific differentiation assays in two papers: one ap-
peared relevant to the intended indication (periodontitis)
and one less obviously so (spinocerebellar ataxia). Other
Fig. 3 Background information on cells used in clinical trials. A Sources of the tissue from which MSCs were derived. B Reported use of
autologous and allogeneic MSCs. C Nomenclature used to describe the cells used in the clinical trials
Fig. 4 Extent and stringency of characterisation. A Number of articles reporting each category of characterisation. B Stringency of characterisation
reported at each clinical phase of development (coloured as in A). C Number of phenotypic markers, and viability, evaluated in articles that
reported values/averages
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Fig. 5 Phenotypic characterisation and viability. The minimal criteria recommended by ISCT for identification of MSC are shown between the
black bars on the y-axis. A Analysis of individual markers reported in the clinical data set, showing whether an attribute was performed with
results reported, whether it was performed but no results stated, or not mentioned in the study report. B Number of studies that addressed each
attribute, defined by extent of reporting for each marker. Required expression or absence of a marker according to the ISCT recommendation is
indicated on the y-axis
Fig. 6 Differentiation and other functionality assessments. A Frequency of functionality assessments. B Nomenclature (stem/stromal) in relation to
potential mechanism of actions relevant to each study indication. C Evaluation of MSC differentiation capacity (multi-potentiality) in relation to
the mechanism of action anticipated for each study
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functional assays were performed in 4 studies: protein
expression in two and assays mentioned but not de-
scribed in two others. There was no significant associ-
ation between MOA and the cell description used;
mesenchymal ‘stem’ versus ‘stromal’ cell (Fig. 6B) or be-
tween MOA and demonstration of differentiation cap-
acity (Fig. 6C).
Papers were examined for claims of compliance with
ISCT criteria and the extent to which compliance was
actually demonstrated in the paper. Reference was made
to standard criteria in 16 papers, of which 10 claimed
that the cells used in the study complied with the ISCT
criteria (taken to mean both phenotype and multi-
lineage differentiation potential). A further 5 papers
stated that the cells were consistent with the phenotypic
profile alone and one claimed compliance with the
phenotype recommended by the ISCT/International
Federation for Adipose Therapeutics and Science (IFAT
S) joint statement for identification of cultured adipose-
derived stromal cells (89). However, none of these pa-
pers presented data to confirm full compliance of the
cells with the standards’ recommendations.
Discussion
Our analysis has demonstrated that MSC-based clinical
trials are being conducted across many countries and for
a wide range of indications. The dataset covered 27
countries, 46 specific indications and 11 routes of ad-
ministration and reported on trials across the spectrum
of clinical development stages. Consistent with other
analyses [28], we found that the greatest proportion of
trial reports covered early trials of safety and initial effi-
cacy (phase I/IIa).
We uncovered a surprising lack of MSC characterisa-
tion in published reports. The characterisation is critic-
ally important in clinical studies of cell therapies: even
with a validated production process, confirmation of the
viability and phenotypic identity of the cells being ad-
ministered to the patient should be the absolute mini-
mum requirement. Assessment of non-target cell types
should also be evaluated taking into consideration po-
tential contaminating cells in the source tissue. The ex-
tent to which such contaminants may be selected
against during the manufacture of the MSC product will
vary; thus, evaluation of non-MSC markers should be
undertaken as part of quality control, specifically the
purity of the clinical cell population. We found that 59
studies (70%) reported some flow cytometric assessment
of cell surface markers, most commonly the typically
quoted positive expression of CD73, CD90, CD105 and
lack of haematopoietic markers CD34 and CD45. Our
ranking of reported surface markers by frequency mir-
rored those in a review of the Investigational New Drug
applications submitted to the US FDA [54], reinforcing
the idea that despite issues with the ISCT recommenda-
tion [48, 55], it has become embedded in the field. Other
markers typically used as a positive or negative in MSC
populations were reported far less frequently. Three
markers suggested in the literature as putative markers
for identification and/or selection of MSCS (CD271 [56],
MSCA-1 [57] and SSEA-4 [58]) were not adopted in any
of the studies we analysed. CD146 [7, 59] and STRO-1
expression were each reported in two studies [60, 61],
the latter marker once as a positive identifier of bone
marrow-derived cells and once as a negative identifier
for expanded adipose-derived MSC.
Considerable heterogeneity of approach was detected
amongst papers reporting numerical values for charac-
terisation attributes. The largest subset of studies in-
cluded average values covering only one characterisation
attribute (viability), whereas in the second largest group,
8 studies each reported 8 or 9 attributes, and the re-
mainder covered fewer markers. This suggests that char-
acterisation of the cell population is either undertaken
thoroughly or is not seen as a priority. There was no as-
sociation between the number of characterisation tests
reported and the year of publication, suggesting that
characterisation, or the reporting of it, is not increasing
in importance over time amongst authors.
Only one paper claiming compliance with the surface
antigen profile recommended by the ISCT provided data
sufficient to confirm this. In 10 papers claiming compli-
ance, the antigen profile reported was not consistent
with ISCT: either the marker panel was incomplete or
expression values were not consistent with the ISCT rec-
ommendation. In the other 5, no data were presented to
assess the stated compliance. It should be noted that
whilst the ISCT minimal criteria statement for MSCs ex-
plicitly confined its application to research, the IFATS/
ISCT joint statement on culture-expanded adipose-
derived stromal/stem cells [62] was presented as a pre-
liminary tool in the development of standards for clinical
use of these cells. It is inappropriate to second-guess the
rationale for control of the investigational medicinal
product in individual studies, but given that about 17%
of studies referred to the ISCT criteria, we may speculate
that there is some appetite for reference to an external
standard.
Tri-lineage differentiation to osteogenic, chondrogenic
and adipogenic lineages in vitro was not demonstrated
in 7 of the papers claiming ISCT compliance. In the only
paper in which full compliance with the ISCT surface
antigen profile was demonstrated, differentiation was
not mentioned. The clinical relevance of in vitro differ-
entiation assays, performed or mentioned without data,
in 24 studies, was questionable in many instances and
may reflect an intention to comply with ISCT recom-
mendations rather than an attempt to confirm biological
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activity relevant to the indication being investigated. Dif-
ferentiation assays were conducted in 30% of the studies
for indications likely to rely on the secretion of immuno-
regulatory or anti-inflammatory molecules. Assessment
of MSC differentiation capacity would be important for
indications based on mechanisms of action involving dif-
ferentiation. However, there were more studies in which
MSC differentiation was demonstrated for an immune
MOA, and fewer for paracrine and multiple MOA than
expected.
The majority of papers (67%) described the MSC
population as mesenchymal stem cells, with stromal be-
ing used in most others (31%), even though stem-related
properties were not implied as being relevant for the im-
munomodulatory and secretome-based indications being
investigated. There was no significant association be-
tween MOA and nomenclature (stem/stromal).
Distinct from multi-lineage differentiation character-
isation of MSCs, only six papers included reference to a
potency or functionality assay. The relationship between
potency/functional assay and clinical indication in these
studies was fairly clear in four cases: thrombospondin
expression for osteoarthritis; inhibition of T cell prolifer-
ation and cytokine expression in bronchiolitis obliterans
syndrome for which immunomodulatory mechanisms
were postulated; and osteogenesis for periodontitis and
neurotrophic factor secretion in amyotrophic lateral
sclerosis. In the remaining two papers, a potency assay
was mentioned but there was no information provided
concerning the assay performed. Immunoselection of
CD271+ cells from the initial bone marrow aspirate was
anticipated to deliver increased beneficial cytokine and
immunomodulatory properties in one study, yet it did
not report confirmation that the population adminis-
tered maintained its high CD271 expression following
culture expansion. Although the vast majority of studies
were an early phase, evaluating the biological properties
of the cells being administered is essential for the field
to develop.
A key finding of this analysis is that reporting of char-
acterisation information in MSC therapy clinical trials is
poor. Most published reports of clinical trials did not in-
clude convincing data on the identity of the MSCs; in
other words, the study drug. For small molecules and
well-defined biotechnology-derived drug products, this is
not an issue: the structure of the drug may be clearly de-
fined by its chemical/biochemical composition and iden-
tified to other researchers by a statement of
international non-proprietary name or structure. In the
case of cell-based ATMPs, the key attributes of the study
drug cannot be conveyed by a single term such as ‘mes-
enchymal stem cell’ due to well-documented difficulties
in problems defining this cell type [19, 63, 64] and the
impact of tissue source, processing, donor and other
factors on expression profile and therefore potentially
relevant potency and clinical effect [65]. Whilst we rec-
ognise that reference to previous work is a normal part
of academic reporting, this is not acceptable for clinical
trials on investigational medicinal products: the product
being administered to patients is required to be tested or
a validated surrogate material in the case of autologous
products with limited cell availability. In authorising a
clinical trial, regulatory authorities in major jurisdictions
do not normally accept data generated from different
cell sources, donors, processes or manufacturing sites,
nor from previous studies. The field must include much
more detail to support the comparison of trials and to
provide a clear understanding of exactly what drug sub-
stance has been tested.
We found that only 62% of the studies included data
on cellular identity, purity and viability. It is recognised
that characterisation may have been performed and not
included in the publication; indeed, this is very likely
given that more extensive data would normally be re-
quired to obtain a clinical trial authorization in many ju-
risdictions including the USA, EU, Japan, Australia and
Canada. Increasing depth of characterisation is expected
as clinical development proceeds and is considered es-
sential to assess product consistency and process con-
trol. Given that characterisation data will have to be
generated for clinical trial approvals and in particular for
marketing authorisation applications, it could be argued
that there is little incentive for clinical trial publications
to include any detail of cell populations. Certainly, it
may be the case that commercial interests mitigate
against such disclosure: this is a relevant consideration
in later development and may conflict with intellectual
property concerns. For example, enrichment of a specific
population based on a particular surface antigen may po-
tentially facilitate increased functional protein expression
or differentiation capacity, an interest which a company
may not wish to emphasise.
However, we argue that clinical trial publications
should include at least basic information on the cell
population—the drug substance—being administered,
for the following reasons:
1. Researchers should be able to evaluate reports for
external validity: the literature on MSCs includes
increasing numbers of clinical trial reports that
physicians may use to guide treatment decisions. It
is therefore reasonable to expect that evidence be
provided to demonstrate that the cells are likely to
be ‘MSCs’ for comparison purposes.
2. Clinical trial outcomes cannot be assessed in their
proper context if the test product has not been
defined. The ISCT criteria were not intended to
represent release criteria for cells for clinical use
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and in any case such recommendations do not
constitute binding regulatory requirements. In the
absence of accepted definitive requirements for
clinical ‘MSCs’, studies purporting to use MSCs
should include, minimally, evidence of identity,
purity and viability of the test population.
3. The community involved in research on clinical
application of MSCs must recognise that MSCs are
subject to potential misuse on a global scale. The
term ‘stealth research’, applied originally to medical
start-ups promoting innovative products and solu-
tions without peer-reviewed evidence [66], might
also be applied to clinics offering unlicensed cell
therapies for a multitude of clinical conditions. Such
clinics may not offer peer-reviewed evidence of the
validity of their treatments, thereby avoiding scru-
tiny and engagement with the research community.
Reliance on ‘in-house’ (unpublished) data may be
suggestive that the technology being promoted is
unreliable [67]. Reports with poor definitions of the
study drug may be particularly likely to be misre-
presented in these circumstances. Importantly, the
promotion of unapproved treatments by unregu-
lated clinics may also damage the reputation of the
research field and erode public trust in the scientific
community when patients are unable to distinguish
between properly regulated and controlled therapies
from offerings from unregulated clinics [68].
Consideration of the related area of bone marrow as-
pirate (BMA) therapy illustrates the problem of poor
definition in clinical trial reporting. A study by Piuzzi
et al. [34] assessing reporting of quantitative data in clin-
ical trials showed that only 30% of the studies gave
quantitative details of the composition of the test prod-
uct, and none of the papers included sufficient detail
that another researcher could seek to replicate the pro-
duction of the BMA preparation. A review of studies of
various cellular preparations used in intra-articular injec-
tion to the knee, including platelet-rich plasma (PRP),
mixed adipose-derived nucleated cells, mixed blood-
derived nucleated cells and culture-expanded bone mar-
row adherent cells [30] identified that whilst the majority
reported qualitative surface marker characterisation,
only one included a functional assay, and only one study
applied the term ‘MSC’ correctly within the context of
the ISCT minimal criteria. Similarly, studies on PRP
were shown to poorly define preparation protocol or de-
fine the study treatment in detail [32].
The need for better reporting of stem cell therapy clin-
ical trials, including standardisation of terminology and
nomenclature, better definition of cell sourcing and
manufacture, and objective characterisation of cellular
populations administered to patients has been
highlighted [27, 30–32, 34]. Recognising the issues aris-
ing from poor reporting of cell therapy clinical trials,
and the need to improve standardisation of reports to fa-
cilitate comparisons between trials, an international con-
sensus on a communication of cell therapy studies has
been developed [31]. In this document, the use of vali-
dated methods (Delphi) to develop a consensus amongst
around 40 experts produced a recommendation for a
standardised reporting format to describe cell therapies:
Donor, Origin of tissue, Separation (production method),
Exhibited cell characteristics, Site of delivery (DOSES).
The E (exhibited cell characteristics associated with be-
haviour) attributes recommended for reporting included
surface antigen expression, functional or performance
attributes and physical attributes of the cell product. Al-
though not focussing specifically on MSCs, these princi-
ples should be valuable especially in this most widely
used cell type. We strongly endorse the proposal identi-
fied in this consensus paper as it proposes a core set of
attributes for the reporting of cell therapy studies: donor,
tissue origin, manufacture/processing, cellular character-
istics and route of administration. Similarly, minimum
reporting standards including checklists specific for PRP
and MSC-based products have been recommended via
Minimum Information for Studies Evaluating Biologics
in Orthopaedics (MIBO) [33].
The analysis undertaken here provides a detailed illus-
tration of the lack of published detail in MSC clinical tri-
als, which is highlighted at a general level in the DOSES
recommendation. In our analysis, poor definition of the
drug substance (phenotypic identity) raises the question
of what exactly was administered to the patients, what
other cell types (impurities) were given with it and what
evidence of biological activity was available. The identity
and purity of the MSC population, coupled with cell via-
bility, should be the absolute minimum requirement for
the identification of the drug substance under evalu-
ation. Of particular concern is the observation that in 36
studies (43%), there was no mention of viability: this
most fundamental parameter was not, apparently, con-
sidered to be a sufficiently important attribute or con-
tributor to the effect under evaluation to be reported.
Therapeutic efficacy may not require viable cells [69],
with some effects of MSCs potentially involving products
of dead or apoptotic cells, or phagocytosis by recipient
monocytes [70, 71]; however, the viability of any cell
preparation would seem to be an essential property to
be determined.
Science and medicine journals are increasingly adopt-
ing standards to which authors must comply for particu-
lar publication types: for example, the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines for reporting of meta-
analyses are now required by 181 journals in the health
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sciences area [72]. The expectations for reporting of ran-
domised controlled clinical trials (RCT) are addressed by
the CONSORT (Consolidated Standards of Reporting
Trials) statement [73], first published in 1996 and up-
dated in 2010 [74] which establishes minimum elements
of trial design and analysis to be included in RCT re-
ports. The statement includes an explicit requirement
for the intervention to be described in sufficient detail to
allow another researcher to replicate the study, in par-
ticular details of the drug and its administration.
The specific CONSORT provisions for herbal medi-
cines can be considered a model for reporting of cell-
based product trials, because of similar difficulties in de-
fining the drug substance. Thus, the CONSORT exten-
sion for herbal medicines [75] recommends the
inclusion of exact plant species (binomial), part(s) of the
plant used, extraction and purification methods and con-
ditions, details of composition and methods of analysis.
These recommendations complement, to an extent, the
DOSES recommendations and support by analogy the
idea of a common required set of data to support the
identity of any cell-based product administered during a
clinical trial. All three recommendations (DOSES, CON-
SORT and MIBO) are consistent in promoting a min-
imal data set to allow for increased transparency and
comparability of published reports.
We also examined the publication policy of key journals
in the cell therapy field in respect of clinical trial reports
and requirements for reporting of cell characterisation.
Most expect a checklist for compliance with CONSORT,
which specifies information to be included in the report of
a clinical trial, and compliance with the International
Committee of Medical Journal Editors (ICMJE) policy, a
good practice umbrella aimed at all authors, reviewers and
publishers of biomedical research. It is notable that we
have been unable to locate any specific journal policies re-
garding minimal datasets for cell therapy clinical trials,
when these therapies arguably represent the greatest chal-
lenge to clear and transparent identification of study drugs
used in human subjects.
The introduction of the CONSORT reporting recommen-
dations for RCT reporting has helped to improve the strin-
gency and completeness of publications in the literature [76,
77]. There are, understandably, concerns around the burden
on journal staff of checking compliance, and the possible in-
advertent distortion of the literature if non-compliant studies
is not submitted for publication [78]. Nevertheless, this
should be a secondary consideration to maximising the sci-
entific value of published clinical trials, and therefore, we en-
dorse the principle of minimum reporting content, and the
adoption of appropriate guidelines for reporting of cell ther-
apy clinical trials; in particular, a detailed description of the
study drug should more adequately reflect the true state of
research in this increasingly important area.
We should emphasise that our conclusions are based
on published data. It is fully appreciated that trial spon-
sors will have detailed data held internally and may well
have completed additional tests beyond those in their
published reports. Scrutiny of available results of clinical
trials at https://www.clinicaltrialsregister.eu/ and https://
clinicaltrials.gov/ did not reveal any additional character-
isation data not published in the papers themselves. Our
main objective in reporting this analysis, however, is to
highlight the current extent of published characterisation
and to suggest that improvements in this regard could
have significant benefits to the research community.
Given the key role of journals in the dissemination of re-
search, we recommend from our evidence that mini-
mum reporting standards for cell therapy clinical trial
reports are universally adopted, perhaps as a further ex-
tension analogous to the herbal medicines extension for
the CONSORT guidelines.
Our study did not set out to capture clinical trial out-
comes, for a number of reasons. We recognised pro-
spectively that analysis of the outcome of a trial would
be far more complex than a binary determination of
‘successful/not successful’. Many studies were early
phase and outcomes focussed on safety rather than effi-
cacy. Primary endpoints and their assessment criteria
often varied across studies for the same indication, and
in many papers, the results were reported as a series of
observations rather than analysed as an intent-to-treat
population. Given that many of the papers reported early
phase studies, it was not surprising that some papers did
not opine on the success of the treatment but positioned
the work as preliminary/feasibility for which follow-up
studies would be required. Assessing any correlation be-
tween the extent of characterisation and outcome would
require accounting for a whole range of clinical vari-
ables, including detailed inclusion/exclusion criteria,
diagnostic criteria, baseline patient demographics,
methods of treatment, clinical monitoring and specific
outcomes assessment. The dose of cells would be ex-
pected to influence treatment outcomes, but the com-
plexity of measuring this fundamental parameter is
highlighted by the lack of characterisation data in itself:
even if all studies reported cellular viability (they did
not), the inherent assumptions around the homogeneity
of this cellular population implies that cell number
should relate to clinical effect when it is very likely that
only a small subset of administered cells would have the
intended activity. A wide range of clinical conditions was
included in the study. Some of these indications, such as
acute myocardial infarction and spinal cord injury, were
represented commonly, whereas for others, e.g. meniscus
repair and bronchiolitis obliterans syndrome, only one
paper was included in the data set. This, coupled with
the complexity of any outcome variable and the number
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of papers, prevents statistically robust correlations been
the degree of characterisation and the trial outcome be-
cause the data stratification needed would lead to very
small sample sizes.
Adequate disclosure of clinical treatment and transpar-
ency regarding preparation and analysis of the investiga-
tional drug product should help to improve the overall
credibility of the cell therapy field. If there is a higher ex-
pectation for peer-reviewed evidence, coupled with trans-
parency and meaningful levels of detail, it should become
easier to determine the true balance of evidence for and
against the use of particular therapies in specific indications.
Thus, the results of our study on MSC clinical trials sup-
port and exemplify the need for standardised minimum
reporting requirements for cell therapy clinical trials.
Conclusions
Overall, this study highlights the apparent paucity of
characterisation data in MSC clinical trial reports. The
extent of characterisation being performed does not ap-
pear to be increasing over time, and our data suggest a
considerable variation in approach towards the necessity
of characterising cell populations. Much greater consid-
eration of potential mechanisms of actions should be ex-
pected for publication of trials beyond an initial
feasibility and safety (phase I) study. Our study findings
are consistent with several recent recommendations for
improvement in characterising cell therapy populations
generally and exemplify the need for better reporting in
respect of MSCs, which are so widely used in many indi-
cations. We recommend the adoption of minimal stan-
dards of cell population identification and testing to be
required in published reports of MSC clinical trials.
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